Osaterone acetate

Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs[1].

Product Specifications

CAS Number

[105149-00-6]

UNSPSC

12352005

Hazard Statement

H302-H361

Target

5 alpha Reductase; Androgen Receptor

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology

Smiles

CC(O[C@]1([C@@]2([C@@]([C@@]3([H])[C@]([C@@]4(C(C(Cl)=C3)=CC(OC4)=O)C)([H])CC2)([H])CC1)C)C(C)=O)=O

Molecular Formula

C22H27ClO5

Molecular Weight

406.90

Precautions

P264-P270-P280-P330-P405-P501

References & Citations

[1]Niżański W, et al. Comparison of Clinical Effectiveness of Deslorelin Acetate and Osaterone Acetate in Dogs with Benign Prostatic Hyperplasia. Animals (Basel) . 2020 Oct 21;10 (10) :1936.